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ABSTRACT 
Background and Purpose:         To better understand opioid signaling in visceral nociceptors, 
we examined the expression and selective activation of mu (MOR) and delta opioid receptors 
(DOR) by dorsal root ganglia (DRG) neurons innervating the mouse colon. 
 Experimental Approach:  DRG neurons projecting to the colon were identified by retrograde 
tracing. DOR-GFP reporter mice, in situ hybridization, single-cell RT-PCR, and MOR-specific 
antibodies were used to characterize expression of MOR and DOR. Voltage-gated Ca2+ currents 
and neuronal excitability were recorded in small diameter nociceptive neurons (capacitance < 
30pF) by patch clamp and ex vivo single-unit afferent recordings were obtained from the colon. 
Key Results:  In situ hybridization of oprm1 expression in Fast Blue-labeled DRG neurons was 
observed in 61% of neurons.  MOR and DOR were expressed by 36-46% of colon DRG neurons, 
and co-expressed by ~25 % of neurons. MOR and DOR agonists inhibited Ca2+ currents in DRG 
and these effects were blocked by opioid antagonists.  One or both agonists inhibited action 
potential firing by colonic afferent endings.  Incubation of neurons with supernatants from 
inflamed colon segments inhibited Ca2+ currents and neuronal excitability. The MOR but not the 
DOR antagonist, inhibited the supernatant effects on Ca2+ currents, whereas both antagonists 
inhibited their actions on neuronal excitability. 
Conclusions and Implications: A significant number of small diameter colonic nociceptors co-
express MOR and DOR and are inhibited by agonists and endogenous opioids in inflamed 
tissues. Thus, opioids that act at MOR or DOR or their heterodimers may be effective in the 
treatment of visceral pain. 
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INTRODUCTION 
Abdominal pain is a debilitating symptom for patients with chronic disorders such as 
inflammatory bowel disease (IBD), resulting in emotional suffering, physical disability, and 
increased medical costs (Bielefeldt, Davis & Binion, 2009; Srinath, Walter, Newara & Szigethy, 
2012). Opioid use has markedly increased in the past decade. Five -13% of patients with IBD are 
prescribed chronic narcotics in the outpatient setting (Cross, Wilson & Binion, 2005; Hanson, 
Loftus, Harmsen, Diehl, Zinsmeister & Sandborn, 2009; Targownik, Nugent, Singh, Bugden & 
Bernstein, 2014), and opioid use reaches 70% for inpatients (Long, Barnes, Herfarth & 
Drossman, 2012). Opioid drugs can be efficacious, but in some settings can also be detrimental 
due to escalating dosing with its attendant side-effects (e.g. nausea, cognitive impairment, 
constipation) and, paradoxically, an opioid-driven increase in abdominal pain, referred to as 
narcotic bowel syndrome (Drossman et al., 2012). Understanding how opioids alter the 
excitability of peripheral dorsal root ganglia (DRG) neurons is particularly important because 
50 - 100% of the analgesic effect of systemically administered opioids are mediated by opioid 
receptors on these neurons (Stein & Machelska, 2011). 
These peripheral opioid mechanisms also become increasingly important as inflammation 
progresses, due to an enhanced endogenous opioid system (Boue et al., 2014; Stein, 2015; Stein 
& Machelska, 2011). During chronic inflammation, accumulating tissue CD4+T cells secrete β-
endorphin, met-enkephalin, and dynorphin A, the endogenous ligands of opioid receptors. 
These endogenous opioids play an important role in enhancing analgesia and mitigating opioid 
tolerance by signaling to intestinal nerve terminals of DRG neurons (Fichna et al., 2012; Stein, 
2015; Stein & Machelska, 2011; Verma-Gandhu et al., 2006). Given the importance of these 
actions, targeting this endogenous pathway could provide a means to enhance analgesia during 
inflammation. However, the opioid receptors mediating gastrointestinal analgesia have not been 
adequately described. 
 DRG neurons express delta, mu, and kappa (DOR, MOR, KOR) G protein-coupled receptors that 
inhibit neuronal excitability and release of inflammatory neuropeptides (Stein, 2015). However, 
the functional expression of these receptors on specific subsets of DRG neurons has been an 
area of ongoing controversy (Bardoni et al., 2014; Beaudry, Dubois & Gendron, 2011; Scherrer 
et al., 2009; Woolf, 2009; Zhang, Bao & Li, 2015). In the somatosensory system, recent studies 
(Bardoni et al., 2014) suggest a divergence of MOR and DOR expression, with DOR being mainly 
expressed on myelinated A-type fibers and MOR-DOR co-expression in less than ten percent of 
DRG neurons. Compared to the somatosensory pathways, there is reportedly little expression of 
DOR on DRG neurons innervating the viscera, suggesting opioids only signal to MOR in the GI 
tract. (Scherrer et al., 2009). Despite these potentially important differences, little is known 
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about the expression of opioid receptors on DRG neurons that innervate the intestine. Such 
studies are needed to improve our understanding of the role of opioids in modulating visceral 
pain, particularly given the known interactions between MOR and DOR including 
heterodimerization, and the mechanisms of inflammation-induced plasticity of opioid 
signaling(Stein, 2015). 
 Technical issues have confounded the interpretation of studies of opioid receptor expression, 
particularly of DOR (Stein, 2015; Zhang, Bao & Li, 2015). We therefore studied DOR eGFP 
reporter mice, where DOR expression has been previously validated in neurons (Poole, Pelayo, 
Scherrer, Evans, Kieffer & Bunnett, 2011; Scherrer et al., 2009). We used combined 
neuroanatomical and electrophysiological techniques to determine the expression of MOR and 
DOR by colonic DRG neurons. Voltage-gated calcium currents and measures of neuronal 
excitability provide a functional measure of opioid receptor signaling given their key role in 
presynaptic inhibition of neurotransmitter release in central terminals in the dorsal horn of the 
spinal cord, and in generation of action potentials in DRG neurons. We found MOR and DOR 
were expressed on colonic DRG neurons and examined the effects on nociceptive signaling of 
selective opioid agonists and endogenous opioids in inflamed colons.  
METHODS 
Animals and identification of colon DRG neurons 
 The Animal Ethics Committee of Monash University, the University of Adelaide and the South 
Australian Health and Medical Research Institute (SAHMRI), and Queen’s University approved 
procedures using animals.  Investigators adhered to the ARRIVE and BJP guidelines for animal 
experimentation. In all groups, mice were males that were group housed (4-5 per cage) and 
maintained under temperature (22±4°C) and light- (12 h light/dark cycle) controlled conditions 
with free access to food and water.  Specific strain and housing details for each group are outline 
below.   
Chronic colitis was induced in C57Bl/6 male mice (Charles River Laboratories) by oral 
administration of 2% DSS in the drinking water for three cycles of 5 days alternating with 5 
days of normal water, as previously described (Valdez-Morales et al., 2013). At day 30, control 
and DSS mice were killed by isoflurane overdose and cervical transection and colons were 
excised. Colonic supernatants were generated by cutting the colon into 5 mm segments and 
incubating each of them overnight in 250 μl of RPMI medium with 10% fetal calf serum, 
penicillin/streptomycin and gentamycin/amphotericin B at 37°C, with 95% O2 and 95% CO2. 
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Supernatants were removed, sterile-filtered and stored at -80 °C. Our previous studies have 
shown that incubation of neurons overnight in supernatants evoke similar electrophysiological 
changes to those observed in retrogradely labeled neurons from the colon of cDSS mice 
(Ibeakanma et al., 2011; Valdez-Morales et al., 2013) 
 To identify DRG neurons innervating the colon, Fast Blue injections were made into the wall of 
colon, as previously described (Ibeakanma et al., 2011) and Fast Blue retrograde labeled 
neurons in DRG were identified in subsequent imaging. 
 
 Immunofluorescence 
Colonic DRG neurons were identified by Fast Blue-labeling in DOReGFP knock-in mice (male, 6-
8 weeks)(Scherrer et al., 2006).  Mice caged with sawdust bedding and fed Barastoc chow 
(Ridley, AgriProducts, Victoria, Australia).   After 7 days, mice were injected with the DOR 
agonist SNC80 (10 mg/kg s.c. in acidified saline solution, 30 min) and killed by cervical 
dislocation. Lumbosacral DRG were harvested and fixed in paraformaldehyde (4% solution in 
PBS, 2 h on ice). DRG were cleared of fixative (3 x PBS washes), cryoprotected in 30% sucrose 
(w/v in PBS), and embedded in Optimal Cutting Temperature solution (Sakura Finetek). DRG 
were cryosectioned (12 μm) and every fifth section was collected onto positively charged slides 
(Superfrost Plus). Tissues were air-dried before blocking (5% normal horse serum, 0.1% Triton 
X-100 in PBS containing 0.1% sodium azide, 30 min, RT). Sections were incubated with primary 
antibodies: chicken anti-GFP, Abcam, ab13970, 1:500; rabbit anti-MOR (UMB3), Abcam, 
ab134054, 1:250, Lupp et al. 2011 http://www.ncbi.nlm.nih.gov/pubmed/20851148) diluted in 
blocking buffer overnight at 4°C. Sections were washed (3 x PBS), incubated with secondary 
antibodies (donkey anti-chicken Alexa Fluor 488, 1:500; donkey anti-rabbit Alexa Fluor 568, 
1:500, Invitrogen/Thermofisher), washed (3 x PBS) then mounted (Prolong Gold, 
Invitrogen/Thermofisher). Samples were imaged using a Leica TCS-SP8 confocal microscope 
using a 20x oil immersion objective. Images were of 1024x1024 pixel resolution and 16 bit 
depth. 
 
 In situ hybridization 
Male mice were caged with sawdust bedding and fed Barastoc chow (Ridley, AgriProducts, 
Victoria, Australia).    They were killed by cervical dislocation and trigeminal ganglia dissected. 
RNA was extracted from the ganglia using the Qiagen (Charsworth, California, USA) RNAEasy kit 
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and was reverse transcribed using Superscript III (Invitrogen, Victoria, Australia)(Bron, Wood, 
Brock & Ivanusic, 2014). cDNA for mouse OPRM1 was amplified by RT-PCR.  The following 
forward and reverse primers were used: TATACCAAAATGAAGACTGCCACCA(mOPRM1_F352) 
and GAATTCTAATACGACTCACTATAGGGAGACATCGTTTGAAGTTTTCATCCAGG 
(mOPRM1_R1103_T7). The design of the reverse primer includes the T7 promoter sequence 
(underlined), which allows the PCR products to be used directly for the generation of 
digoxigenin (DIG)-labeled antisense cRNA probes by in vitro transcription with T7 RNA 
polymerase (Roche Products, Dee Why, NSW, Australia). In situ hybridization combined with 
retrograde tracing and immunohistochemistry was performed on cryosections of mouse colonic 
DRG neurons, as described (Bron, Wood, Brock & Ivanusic, 2014). An antibody against HuC/D 
was used as a pan-neuronal marker (mouse monoclonal, #A21207, Invitrogen; 1:1000) and 
labeling was detected using a donkey anti-mouse secondary antibody (Alexa Fluor488 
conjugated, 1:500, Invitrogen). 
Sections were scanned using 10x or 20x objective magnification with a VSlide Fluorescent Slide 
Scanner (MetaSystems, Carl Zeiss, North Ryde BC, NSW, Australia) and stitched together using 
the Metafer platform. Digitized images were exported as TIFF files and processed in Adobe 
Photoshop for panel preparation. 
 
Image analyses 
All DRG sections containing Fast Blue-positive neurons were imaged and analyzed in an 
unblinded fashion. Fast Blue-positive neurons were identified from projected z-stacks and 
coexpression of GFP and MOR immunoreactivities were then determined. Images were 
thresholded to facilitate analysis. Oprm1 expression in Fast Blue- positive neurons was 
determined from fluorescence and bright field image overlays. Neuron sizes were determined 
using ImageJ (area, perimeter, and length) and expressed in μm2 or μm, respectively. Data were 
expressed relative to the total number of Fast Blue-positive neurons. 
 
Isolation of DRG neurons for electrophysiological studies and single-cell PCR 
Male mice (C57Bl/6, Charles River Laboratories) were fed PMI lab chow (Purina USA) mouse 
#5015 and cage bedding contained a combination corn cob bedding that was changed every 14 
days. DRG neurons were acutely dissociated as described (Ibeakanma et al., 2011; Valdez-
Morales et al., 2013). C57Bl/6 mice (Charles River) were killed with i.p. ketamine/xylazine and 
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DRG from T9-T13 were dissected. Neurons were dispersed and suspended in DMEM (pH 7.2-
7.3, 10% FCS, 1000 U ml-1) (Inamed Biomaterials, Fremont, CA, USA) cover slips and incubated 
in 95% O2 and 5% CO2. Two hours after cells were applied to cover slips in 24 well plates, the 
well plates were incubated with the supernatant/F12 medium (mixture 1:10) and incubated 
overnight (16-23 h) until retrieval for electrophysiological studies.  Acute application of drugs 
was applied the day following acute dissociation of the neurons.  Electrophysiologists were not 
blinded to the application of drug or supernatant.  
 
Single-cell RT-PCR 
Single neurons were processed to obtain cDNA using Superscript III Cells Direct cDNA Synthesis 
Kit (Invitrogen) according to the manufacturer’s instructions. Briefly, we used single Fast Blue-
labeled small DRG neurons (≤30 pF) from primary cultures. Each neuron was harvested under 
into the patch pipette containing 6 μl of 10X resuspended buffer and 1 μl of RNAseout (2U/μL) 
by applying negative pressure. The content of the patch pipette was expelled into a PCR-tube 
containing 4 μl of 10X resuspended buffer, 2 μl Oligo dT(20) and 1 μl dNTP (10 mM) and the 
reaction was incubated at 70 °C for 5 min and then 2 min on ice. After adding 6 μL 5X RT buffer, 
1 μl of RNAseout (2U/μL), 1 μl of Superscript III reverse transcriptase (200U/μl) and 1 μl DTT 
(0.1M). The sample was transferred to 50 °C for 50 min, the reaction was inactivated by heating 
to 85 °C for 5 min and placed on ice. As negative controls, fluid from the vicinity of the collected 
cells was amplified or template was omitted. PCR reaction contained 0.2 μM primers, 0.5 U Taq 
Polymerase, 2.0 mM MgCl2, 10 mM dNTP, and 10× PCR buffer (Qiagen) (25 μl final volume). PCR 
reaction conditions were 40 cycles of initial activation at 95°C for 5 minutes, denaturation at 
94°C for 30 seconds, annealing at 60°C for 30 seconds, extension at 72°C for1 minute, and final 
extension at 72°C for 5 minutes. PCR was performed using the following intron-spanning mouse 
primers: DOR (NM_013622.3) outer forward, 5′-TTCTGGGCAACGTGCTCGTC-3′; DOR outer 
reverse 5′-CATAGCACACCGTGATGATG-3′ (510-bp product); DOR inner forward, 5′-
TGTTTGGCATCGTCCGGTAC-3′; DOR inner reverse 5′-TGAAGCCAAGACCCAGATGC-3′(320-bp 
product); MOR (NM_001039652.1) outer forward 5′-GTATCTTCACCCTCTGCACC-3′; MOR outer 
reverse 5′-AGGCAATGCAGAAGTGCCAG-3′ (510-bp product); MOR inner forward 5′-
AGGCCCTGGATTTCCGTACC-3′; MOR inner reverse 5′-CATGCGGACACTCTTGAGTC-3′ (272-bp 
product); Actin (NM_007393.3) outer forward 5’-GCCAACCGTGAAAAGATGAC-3’; Actin outer 
reverse 5’-GCACTGTGTTGGCATAGAGG-3’ (556-bp product); Actin inner forward 5’-
GGCTGTGCTGTCCCTGTATG-3’; Actin inner reverse 5’-TCTTCATGAGGTAGTCTGTCAG-3’ (164-bp 
product, Invitrogen). Nested PCR reactions were performed with 1 μl of a 1:10 dilution of the 
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first PCR. The amplification products were analyzed by ethidium bromide staining subsequent 
to agarose gel electrophoresis (2%). 
 
Patch clamp recordings 
All experiments were performed at room temperature as previously described (Valdez-Morales 
et al., 2013). Patch pipettes were fabricated from borosilicate glass capillaries (Warner 
Instruments, Connecticut, USA) and had resistances between 2-4 MΩ. Voltage-clamp recording 
was performed by use of Multiclamp 700B or Axopatch 200B amplifiers, digitized by Digidata 
1440A or 1322A AD converters, and recorded using pClamp 10.2 software (all by Molecular 
Devices, California, USA). Acutely dissociated neurons plated on coverslips were incubated 
overnight (37°C) with colonic supernatants from control and DSS mice with and without 
selective mu and delta agonists and antagonists. Only cells with a resting membrane potential 
more negative than -40 mV were analyzed. We used only small neurons that exhibit properties 
of nociceptors (Capacitance ≤30 pF). 
Barium currents (IBa) flowing through voltage-gated calcium channels (VGCC) were recorded 
using the whole-cell configuration and an extracellular solution consisting of (in mM): 140 
tetraethylammonium (TEA)-Cl, 2 MgCl2, 5 BaCl2, 10 Glucose, 10 HEPES (pH 7.4 adjusted with 
TEA-OH). The pipette solution contained (in mM): 120 CsCl, 1 MgCl2, 10 HEPES, 10 EGTA, 4 Mg-
ATP and 0.3 Na-GTP (pH 7.2 adjusted with CsOH). A calculated liquid junction potential 
(Clampex Junction Potential Assistant) of 10 mV was digitally compensated. After whole-cell 
configuration, the cell membrane capacitance and series resistance were electronically 
compensated 80-85%. For whole-cell IBa, neurons were held at –90 mV and depolarized to 0 mV 
for 100 ms, leaving an interval of 15 s to help minimize rundown. Neurons that showed >10% 
rundown of current amplitude over 10 min were discarded. The whole-cell current was 
measured in DRG neurons held at -90 mV in response to 100 msec voltage steps ranging from –
60 mV to +55 mV in 5 mV increments, once every 5 sec. The steady-state inactivation of VGCCs 
was measured by depolarizing cells to a series of prepulse potentials from –90 to 55 mV for 400 
ms followed by a command potential to 0 mV for 100 ms. Activation and inactivation curves 
were fitted with a single Boltzmann function of the form G/Gmax = 1/(1 + exp[V50 – Vm/k]), where 
G is conductance, Vm is membrane voltage, k is the slope factor, and Gmax is maximal 
conductance. The amplitude of inward currents was normalized to cell capacitance. 
Changes in neuronal excitability in response to acute (min)  or chronic (overnight)  application 
of  agonists or colonic supernatants were measured by recording the rheobase and the action 
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potential discharge at twice rheobase, as previously described using perforated patch clamp 
recordings with amphotericin B (0.24 mg/ml)(Cattaruzza et al., 2011; Ibeakanma & Vanner, 
2010). The extracellular solution was: 140 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 10 D-glucose, 
pH 7.4. The pipette solution was: 110 K-gluconate, 30 KCl, 10 HEPES, 1 MgCl2, 2 CaCl2, pH 7.25. 
The final pipette resistance was 2-5 MΩ in bath solution and the liquid junction potential was 
corrected (12 mV). 
 
Ex vivo colonic afferent recording studies 
Ex vivo single-unit extracellular recordings of action potential discharge were made from 
splanchnic colonic afferents from C57BL/6 male mice (Brierley, Jones (III), Gebhart & 
Blackshaw, 2004; Castro et al., 2013; de Araujo et al., 2014; Hughes, Brierley, Martin, Brookes, 
Linden & Blackshaw, 2009; Hughes et al., 2014). Mice were acquired from an in-house C57Bl/6J 
breeding program (from strain # 000664 originally purchased from Jackson Laboratories) 
within SAHMRI’s specific and opportunistic pathogen free animal care facility.  Cages were filled 
with aspen wood chip bedding.  Food consisted of the Jackson lab diet (5K52 JL RAT and 
MOUSE/AUTO 6F DIET (Cat# ASSPECIAL) and cages contained Jackson lab bedding: CA PURA 
CHIP ASPEN COARSE (Cat# ASPJMAEB). Animals were killed by CO2 inhalation.   In this study 
we focused on high-threshold nociceptive afferents, also termed serosal or vascular afferents. 
These nociceptive afferents have high-mechanical activation thresholds and respond to noxious 
distension (40mmHg), stretch (≥7g) or von Frey hair filaments (2g) but not to fine mucosal 
stroking (10 mg von Frey hairs) (Hughes, Brierley, Martin, Brookes, Linden & Blackshaw, 2009). 
These afferents also become hypersensitive during and after resolution of colonic inflammation 
(Brierley & Linden, 2014; Hughes, Brierley, Martin, Brookes, Linden & Blackshaw, 2009). 
Baseline mechanosensitivity was determined in response to application of a 2 g vfh probe to the 
afferent receptive field for 3 s. This process was repeated 3–4 times, separated each time by 10 s. 
In the first series of experiments, electrophysiologists were blinded to the specific drug being 
tested. Following baseline measurements, mechanosensitivity was then retested after the 
application of either the DOR agonists; DADLE (100nM) or SNC 80 (1000nM) or the MOR agonist 
DAMGO (100nM). These compounds were applied to the mucosal surface of the colon for a 
period of 5 minutes at each concentration via a small metal ring placed over the receptive field 
of interest. Action potentials were analyzed off-line using the Spike 2 wavemark function 
(version 5.21; Cambridge Electronic Design, Cambridge, UK) and discriminated as single units 
on the basis of distinguishable waveform, amplitude and duration. Data are presented as 
spikes/s and are expressed as mean  SEM.  
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In the second series of experiments, C57BL/6 male mice from Charles River were fed PMI lab 
chow (Purina USA) mouse #5015 and cage bedding contained a combination corn cob bedding 
that was changed every 14 days.  They were killed with i.p. ketamine/xylazine and the colons 
were excised. Both DAMGO and DADLE were tested on the same colonic afferent unit (serosal or 
mesenteric unit). Baseline mechanosensitivity was determined in response to a 1g vfh probe to 
the afferent receptive field for 3s. The process was repeated 3-4 times, separated by 10s. 
Mechanosensitivity was then retested after the application of either DADLE (100nM) or DAMGO 
(100nM) to the mucosal surface for 5 minutes via the small metal ring placed over the receptive 
field of interest. Following a 30 minute washout period, mechanosensitivity was retested for 
reversibility. The other agonist was then applied to the receptive field for 5 minutes followed by 
testing of the mechanosensitive response. Reversibility was rechecked after a 30 minute 
washout period. To ensure stability of the unit and adequate washout of the agonist, a unit was 
considered to be inhibited by either the MOR or DOR agonist if the mechanosensitive response 
in the presence of drug was less than 75% of the baseline response and the response following 
washout was within 25% of the baseline response. To further mitigate potential bias from run-
down or incomplete washout of the agonist, the order of the application of DADLE and DAMGO 
was altered for each experiment.  Investigators were not blinded to the drug being tested. 
 
Statistical analyses 
Data were analyzed using Prism 6 or 7 Software (GraphPad Software, California, USA) and 
results were expressed as mean  SEM. Differences between groups were examined by paired or 
unpaired T-tests. Differences between multiple groups were examined using ANOVA and a 
Bonferroni or Dunnett’s post-hoc test. The post hoc test was only applied when the F statistic 
indicated significance.  Statistical analysis was applied to experiments where neurons were 
obtained from at least 5 animals.  The afferent nerve recordings (1-2 single units obtained per 
colon of each animal; 1 unit = 1 single axon recording) shown in Fig. 3B-D were obtained from 
fewer than 5 animals for each drug tested and therefore no statistical analysis was performed.  
A p value < 0.05 was considered to be significant and only reported as *P <0.05 as per British 
Journal of Pharmacology guidelines. In patch clamp studies, the number of neurons and animals 
differed per dataset within a given experiment because each drug concentration and/or 
antagonist was tested each day plus the accompanying controls.   Drugs or supernatants were 
added to separate wells containing the isolated neurons on small glass plates.  Consequently, the 
numbers varied depending on the success of viable recordings from each plate that had been 
taken from the corresponding wells.    
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Materials   [D-Ala2, D-Leu5]-enkephalin (DADLE), (+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-
1-piperazinyl)-3-methoxybenzyl]-N,N- diethylbenzamide (SNC 80),  and [D-Ala2, N-MePhe4, Gly-
ol5]-enkephalin (DAMGO) were all purchased from Tocris Bioscience (UK) (extracellular 
recordings or Sigma (patch clamp recordings).  (4bS,8R,8aS,14bR)-5,6,7,8,14,14b-Hexahydro-7-
(2-methyl-2 propenyl)- 4,8-methanobenzofuro[2,3-a] pyrido[4,3-b] carbazole-1,8a(9H)-diol 
(SDM25N) and D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) were purchased from 
Tocris Bioscience.  
 
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise 





MOR and DOR are expressed by colonic afferent neurons 
Expression of oprm1 mRNA, the gene for the MOR, by Fast Blue-positive colonic DRG neurons 
was examined by in situ hybridization (Fig. 1A). Positive staining for oprm1 was detected in 
approximately 61% of all Fast Blue neurons (62/101 neurons from 3 animals). In contrast, 
MOR-IR was detected in only 36% of all Fast Blue-labeled neurons (75/210 neurons) (Fig. 1B). 
DOReGFP labeling was detected in 46% of colonic afferents (190/411 neurons from 3 animals). 
Approximately a quarter of all Fast Blue- labeled neurons were positive for both DOR GFP-IR 
and MOR-IR (24%, 58/245 neurons). Colonic afferents that co-expressed DOR and MOR had an 
average soma area of 482±27 μm2 and average maximum soma perimeter of 83±2.4 μm and a 
length (measured in sections containing nuclei) of 27.95 μm ± 0.84 μm. 
To confirm the expression of MOR and DOR on DRG neurons innervating the colon, small 
diameter neurons (< 25 μm) labeled with Fast Blue from C57BL/6 mice (13 neurons from 6 
animals) were individually selected, and expression of MOR and DOR mRNAs was examined by 
single-cell nested PCR. The agarose gel electrophoresis of 13 different neurons detecting 
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expression of MOR and DOR is shown in Fig.1C. Among 13 Fast Blue-labeled small diameter DRG 
neurons, 38% expressed MOR mRNA (320 bp), 46% expressed DOR mRNA (272 bp) and 23 % 
co-expressed MOR and DOR mRNAs.  
 
MOR and DOR agonists inhibit Ca2+ currents in small diameter DRG neurons 
To determine whether MOR and DOR regulate voltage-gated Ca2+ channels, we measured IBa in 
small DRG neurons in response to acute (min) and chronic (overnight) exposure to MOR and 
DOR agonists and their antagonists (DRG neurons obtained from 27 mice). Preliminary 
experiments were conducted to address the contribution of T-type Ca2+ channels to whole cell 
IBa in DRG neurons by comparing currents evoked from holding potentials of -60 mV and -90 
mV.  No difference in current amplitude or time course was observed between holding 
potentials of -60 and -90 mV, suggesting that low voltage-activated T-type channels did not 
contribute to IBa under our recording conditions.   
Consistent with previous findings (Moises, Rusin & Macdonald, 1994; Schroeder, Fischbach, 
Zheng & McCleskey, 1991), superfusion of the MOR agonist DAMGO (100 nM) for 5 min led to a 
significant (63.5%) reduction in IBa currents (data not shown).  Similar reductions in IBa currents 
were observed (63.2%) with overnight incubation of DAMGO (100nM; Fig.2.).  In all subsequent 
experiments, neurons were incubated overnight with MOR agonist (DAMGO) or DOR agonist 
(DADLE). Fig. 2A shows examples of currents recorded from a DRG neuron. DAMGO (0.01-1 μM) 
and DADLE (0.01-1 μM) reduced the amplitude of IBa in a concentration-dependent manner (Fig. 
2B). Statistically significant inhibition of these currents was observed in DRG neurons incubated 
overnight with 0.1 μM DAMGO or 0.1 and 1 μM DADLE (Fig.2B). DAMGO and DADLE inhibited IBa 
with similar potency in small DRG neurons (Fig. 2B). There were no changes in the of activation 
(DADLE - k = 5.0 ± 0.47 mV, Vh = -19 .6 ±.54 mV; DAMGO - k = 4.5 ± 0. 4 mV, Vh =-19.0  0.44 )   
and inactivation (DADLE – k = 38.4 ± mV, Vh= -61.8  4.0mV ; DAMGO - k = 23.75.0, Vh =-61.5  
6.0  mV).  A scatter plot from all cells incubated with a maximum concentration (1 μM) of 
DAMGO and DADLE showed that DAMGO inhibited IBa in 7/9 cells and DADLE inhibited IBa in  
17/20 cells (data not shown). The inhibition of IBa evoked by DAMGO and DADLE was blocked 
by CTOP and SDM25N, respectively (Fig. 2C).  The antagonists alone had no effect.   
 
DOR and MOR agonists inhibit colonic nociceptors 
We first examined whether MOR and DOR agonists inhibited neuronal excitability of isolated 
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DRG neurons using patch clamp recordings.  We found that an acute (10 min) application of 
either DAMGO or DADLE (100nM) applied to neurons increased the rheobase and increased the 
input resistance (Fig. 3A). They also decreased the membrane potential from baseline (DAMGO 
= -44 .4 ± 0.8 to -49.9 ± .8 mV, p< 0.05; DADLE -44.2 ± .7 to -47.2 ± 1.0 mV, p <0.05).   To 
determine if MOR or DOR agonists modify colonic nociceptor function in intact tissue, we made 
ex vivo colonic afferent recordings from mouse splanchnic high-threshold nociceptors, which 
respond to focal compression and noxious stretch/distension. The DOR agonist DADLE (100nM; 
5 units from 3 animals) inhibited colonic nociceptor action potential firing in response to 
noxious mechanical stimuli (Fig. 3B). Another highly selective DOR agonist, SNC 80 (1000 nM; 5 
units from 3 animals), also inhibited nociceptor mechanosensitivity (Fig. 3C). The MOR agonist 
DAMGO (100nM; 7 units from 4 animals) also inhibited colonic nociceptors (Fig. 3D). The 
percent inhibition by the DOR and MOR agonists was similar (DADLE = 21 ± 6, SNC 80 = 26 ± 8, 
DAMGO = 25 ± 4). 
 We next examined whether MOR and DOR agonists could inhibit mechanosenstivity in the same 
unit. In these experiments, 6/8 units obtained from 8 animals were inhibited by either DAMGO 
(100nM) or DADLE (100nM) (Fig. 4) and of these, three were inhibited by both DAMGO and 
DADLE. In units that were inhibited by DADLE, afferent firing was reduced from 9.55 ± 3.33 to 
6.03 ± 2.50 spikes/s. In units that were inhibited by DAMGO, afferent firing was reduced from 
14.22 ± 2.72 to 8.59 ± 1.5 spikes/s. 
 
Endogenous opioids released from inflamed colon inhibit colonic nociceptors 
Neurons incubated overnight with supernatants from DSS-inflamed colons (Fig. 5A) exhibited a 
significant decrease in amplitude of IBa compared with IBa in neurons incubated with 
supernatants from uninflamed colon or control supernatants (P<0.05, one-way ANOVA with 
Bonferroni post-test).  In neurons incubated with supernatants from inflamed colon, neither 
DADLE nor DAMGO had an additional inhibitory effect on IBa (Fig.5B). 
Dissociated neurons were preincubated with the MOR antagonist (CTOP 1 μM) or the DOR 
antagonist (SDM25N 1 μM) 30 min before incubation with colonic supernatants from control 
and chronic DSS mice and the effects on IBa and neuronal excitability examined. In control 
studies (Fig. 5C), the application of CTOP or SDM25N alone had no effect on IBa. DAMGO (100 
nM) and DADLE (100 nM). In studies of the chronic DSS supernatant Fig. 5C), the inhibitory 
effect of the chronic DSS supernatant on IBa was supressed by pretreatment with the MOR 
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antagonist CTOP, but not with DOR antagonist SDM25N (Fig. 5C) (One-way ANOVA with 
Dunnett’s post-test).  
Given that the inhibition of IBa by endogenous opioids was mediated predominantly by MOR 
activation we examined whether a similar receptor selectively applied to modulation of action 
potential electrogenesis.  We have previously shown that the rheobase of DRG neurons 
incubated in chronic DSS supernatant is increased and the action potential discharge is 
decreased compared to the effects of control supernatant on neuronal excitability and that this 
effect is blocked by naloxone (Valdez-Morales et al., 2013). In the current study (Fig. 5D), both 
CTOP and SDM25N decreased the rheobase (29% each, p < 0.05) and CTOP increased action 




Therapeutic opioids such as morphine and related compounds act predominantly on MORs to 
treat  acute and chronic abdominal pain in patients with disorders such as IBD. However, these 
agents exhibit a significant adverse side effect profile and consequently, there is need for 
alternative therapies and there is a renewed interest in DOR targeted agents (Stein, 2015; 
Woolf, 2009; Zhang, Bao & Li, 2015). A fundamental step towards understanding how opioids 
can be exploited in this clinical setting is to examine the functional expression of MOR and DOR 
in DRG neurons, and in particular whether they are expressed on small neurons including 
nociceptors innervating the colon. Co-expression of these receptors on the same neuron has 
important implications for understanding opioid signaling, given the potential for physical 
interactions and the formation of heterodimers (Geppetti, Veldhuis, Lieu & Bunnett, 2015; Stein, 
2015; Targownik, Nugent, Singh, Bugden & Bernstein, 2014). We found that MOR and DOR are 
co-expressed on a substantial proportion of colonic DRG neurons and that activation of each of 
these receptors by endogenous opioids can inhibit sensory signaling from the intestine. 
(Ibeakanma et al., 2011) 
 There has been considerable controversy regarding the expression of MOR and DOR in DRG 
neurons and whether these receptors are co-expressed in neurons (Rau, Caudle, Cooper & 
Johnson, 2005), (Scherrer et al., 2009; Stein, 2015),(Bardoni et al., 2014; Beaudry, Dubois & 
Gendron, 2011; Joseph & Levine, 2010; Normandin, Luccarini, Molat, Gendron & Dallel, 2013; 
Wang et al., 2010; Woolf, 2009; Zhang, Bao & Li, 2015), and if so, in which populations of 
neurons. Furthermore, differences may exist between the somatosensory and visceral pain 
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pathways (Scherrer et al., 2009). Much of this controversy has been attributed to the lack of 
specificity of receptor antibodies, particularly to DOR, and non-selective effects of high 
concentrations of opioid agonists (Bardoni et al., 2014; Woolf, 2009; Zhang, Bao & Li, 2015). We 
used DOReGFP knock-in mice, in situ hybridization and single-cell RT-PCR to enable specific 
detection of DOR expression (Bardoni et al., 2014; Scherrer et al., 2009; Scherrer et al., 2006). In 
the somatosensory system, recent studies using this mouse model have shown that only 17% of 
DRG neurons express DOR, and that expression was confined to the larger myelinated CGRP 
positive DRG neurons (Bardoni et al., 2014). Only a small proportion co-expressed MOR and 
DOR (~5%). Visceral afferents account for <10% of all DRG neurons (Beyak and Grundy, 2006) 
and therefore we used retrograde tracing techniques to establish the organ specificity of the 
neurons. Using this approach, our immunohistochemical studies found that about 36 % of the 
neurons that innervated the colon expressed MOR and 46 % expressed DOR. Moreover, we 
found that 24% of neurons co-expressed MOR and DOR and many were small diameter neurons, 
a proportion considerably higher than found in the somatosensory system. Similar proportions 
were observed in our single-cell PCR studies of MOR and DOR mRNAs. Thus, our studies suggest 
a much higher proportion of neurons co-express MOR and DOR in the visceral sensory system, 
including small diameter DRG neurons that have properties of nociceptors (Moore, Stewart, Hill 
& Vanner, 2002; Stewart, Beyak & Vanner, 2003). 
 Voltage-gated Ca2+ play a central role in peripheral and central presynaptic modulation of 
neurotransmitter release from DRG neurons (Beyak & Vanner, 2005; Stein, 2015). We recorded 
from small DRG neurons and found that both DOR and MOR agonists inhibited currents and 
neuronal excitability in a significant proportion of neurons. While our patch clamp studies 
(overnight incubation) did not allow sequential testing of opioid agonists to test for functional 
co-expression in the same neuron we showed that a significant subset of DRG neurons 
projecting to the colon co-expressed mRNA and immunoreactivity for MOR and DOR, as 
described above. Moreover, we examined this question directly using single unit afferent 
recordings from the colon to measure the inhibition evoked by selective opioid agonists on 
action potential generation on visceral afferents in response to noxious mechanical stimulation 
(Hughes, Brierley, Martin, Brookes, Linden & Blackshaw, 2009). Here we found that both MOR 
and DOR agonists cause inhibition of action potential firing to these stimuli and that a similar 
proportion of single units responded to both agonists.  We showed that the inhibitory action of 
the DOR agonist DADLE (100nM) on IBa  was completely blocked by the selective DOR antagonist 
SDM25N and that the highly selective DOR agonist SNC 80 (Loriga et al., 2013), evoked a similar 
degree of inhibition of single colonic afferent units to that observed with DADLE.  Together, 
these findings and the functional studies of others (Beaudry, Dubois & Gendron, 2011), suggest 
This article is protected by copyright. All rights reserved. 
small diameter visceral DRG neurons co-express MOR and DOR in a significant proportion of 
neurons. Interestingly, these findings from our single-unit recordings contrast with our recent 
reports using the same colonic afferent recording preparation, whereby KOR agonists only 
inhibited colonic nociceptors from mice during or following a bout of colonic inflammation 
(Hughes et al., 2014). These contrasting observations highlight the respective roles the DOR, 
MOR and KOR play in opioid signaling in different pathological conditions. 
Understanding the expression of MOR and DOR on nociceptive neurons in the GI tract under 
healthy conditions is important for interpreting the effects of  inflammation. Inflammation leads 
to significant plasticity of opioid signaling (Zhang, Bao & Li, 2015), affecting receptor 
expression, G-protein signaling and receptor trafficking. The effect of inflammation on opioid 
signaling pathways can vary considerably between opioid receptor subtype signaling pathways. 
For example, MOR is upregulated (Stein & Machelska, 2011) in inflammation, including studies 
of human IBD (Philippe et al., 2006), whereas DOR appears to be unchanged or down-regulated 
(Ji, Zhang, Law, Low, Elde & Hokfelt, 1995). We and others (Boue et al., 2014; Valdez-Morales et 
al., 2013; Verma-Gandhu et al., 2006) have shown in models of chronic IBD that endogenous 
opioids released from CD4+T cells exert an important analgesic action. Moreover, administration 
of opioid analgesics is needed for IBD patients for the management of severe symptoms and 
complications.  Here we show that during chronic inflammation endogenous opioids inhibit Ca2+ 
currents and neuronal excitability, but in contrast to control neurons where activation both 
MOR and DOR have similar effects, the inhibitory effect on Ca2+ currents is restricted to MOR 
signaling. Further studies are needed to determine the mechanism underlying this altered 
signaling but these findings may suggest that drugs targeting DOR alone in chronic intestinal 
inflammation will exert little direct effect on opioid-induced analgesia mediated by voltage-
gated Ca2+ currents. 
In summary, our study has shown that DRG neurons innervating the colon express MOR or DOR 
and they are co-expressed on a substantial subpopulation of nociceptors. We also found that 
selective activation of both MOR and DOR receptors inhibits Ca2+ currents and mechanically 
evoked action potential discharge from the colon. Further studies are needed in human tissues 
to confirm that these findings in mice translate to humans.  Such findings in humans are 
important for the understanding of the mechanism of drugs that are targeting multiple 
peripheral opioid receptors in the gut, such as the MOR agonist and DOR antagonist, 
eluxadoline, for the treatment of irritable bowel syndrome (Dove et al., 2013).   Furthermore, 
this co-expression is a prerequisite for the formation of MOR-DOR heterodimers and therefore 
these heterodimers may be expressed on a significant number of colonic nociceptors. If so, this 
could have important implications for understanding the actions of drugs designed to disrupt 
This article is protected by copyright. All rights reserved. 
DOR signaling in the GI tract, as this may increase analgesia and mitigate tolerance (Geppetti, 
Veldhuis, Lieu & Bunnett, 2015).  
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Figure 1. MOR and DOR expression on Fast blue-labeled DRG neurons. (A) Representative 
photomicrographs of in situ hybridization of oprm1 expression in Fast Blue-labeled DRG 
neurons (white arrows) and non-Fast Blue-labeled neurons (yellow arrow). Hu antibody 
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staining identifies all neurons in the ganglia. 61% of Fast Blue-labeled neurons expressed oprm 
1 mRNA.  Scale = 100 μm. (B) Representative photomicrographs of DOR expression in ganglia 
from DOReGFP knock-in mouse and double labeling with MOR immunoreactivity (merge). 
Colonic neurons identified by Fast Blue retrograde labeling. 46% of Fast Blue-labeled neurons 
expressed DOR and 24% were co-immunoreactive for MOR/DOR. Scale = 150 µm. (C) A 
representative agarose gel electrophoresis (2%) stained with ethidium bromide to assess MOR 
and DOR mRNA expression in small diameter Fast Blue-labeled DRG neurons. PCR products 272 
bp, 320 bp and 164 bp corresponding to MOR, DOR and β-actin cDNAs, respectively. Lane 1, 
exACTGene 50bp Mini DNA Ladder; Lane 2-13, PCR products from 13 individual small Fast 
Blue-labeled DRG neurons. Neurons 4, 8 and 13 co-expressed MOR and DOR mRNAs. No 
transcripts were amplified from bath fluid or without template (Lane 14 and 15). Of the 13 
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Figure 2. DAMGO (MOR agonist) and DADLE (DOR agonist) inhibited IBa through voltage-gated 
calcium channels on small DRG neurons. (A) Representative whole-cell recording of calcium 
currents induced by depolarization from the holding potential of –90 to 0 mV for 100 ms, 
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represented in the inset above. The currents were obtained from different small DRG neurons 
incubated overnight with DOR agonist (DADLE 0.1 μM) or MOR agonist (DAMGO 0.1 μM). (B) 
Concentration dependency of inhibition of IBa by DADLE (0.01-1 μM) or (C) DAMGO (0.01-1 μM) 
on small DRG neurons. incubated overnight. Treatment with DADLE or DAMGO produced a 
marked decrease in IBa (*p < 0.05, *p < 0.05). Number of cells appears in each bar. Bars 
represent mean ± SEM. *denote statistical significance by one-way ANOVA with Dunnett’s post-
test. The amplitude of inward currents was normalized to cell capacitance. (C) Effects of MOR 
and DOR antagonists on IBa through voltage-gated Ca2+ channels in DRG neurons. Inhibition of IBa 
by DADLE (100 nM) and DAMGO (100 nM), shown in (B) were blocked by SDM25N (1 μM) and 
CTOP (1 μM), respectively. SDM25N and CTOP alone had no effect on IBa. Bars represent mean ± 
SEM. Number of cells appears in each bar * significant difference from control (P < 0.05, one-
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Figure 3.  Patch clamp and ex vivo single-unit afferent recordings showing DOR and MOR 
agonists inhibit colonic afferents.  (A)  Acute application of MOR and DOR agonists (100nM; 
applied for 10 min) inhibits the excitability of isolated DRG neurons (increase rheobase) and 
 
 
This article is protected by copyright. All rights reserved. 
increases input resistance (*p<0.05). (B) Representative recording (left panel) of a colonic 
nociceptor response to von Frey hair probing before and after administration of DOR agonist 
DADLE (100nM). Summary data (right panel) showing DADLE inhibits splanchnic colonic 
nociceptors from healthy mice, n=5 single afferent recordings from axons innervating the colons 
from 3 mice. (C) Representative recording (left panel) of a colonic nociceptor response to von 
Frey hair probing before and after administration of DOR agonist SNC 80 (1000nM). Summary 
data (right panel) showing SNC 80 inhibits splanchnic colonic nociceptors from healthy mice, n 
= 5 single afferent recordings from  axons innervating the colons from 3 mice.  (D) 
Representative recording (left panel of a colonic nociceptor response to von Frey hair probing 
before and after administration of MOR agonist DAMGO (100nM). Summary data (right panel) 
showing DAMGO inhibits splanchnic colonic nociceptors from healthy mice, n = 7 single afferent 
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Figure 4. Ex vivo single-unit recordings showing inhibit DOR and MOR agonists inhibit same 
colonic afferent unit. (A) Representative recording of a colonic nociceptor response to von Frey 
probing before and after administration of MOR agonist DAMGO (100nM).  Following washout 
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of DAMGO, von Frey probing is applied to the same unit before and after administration of 
DADLE (100nM).  (B) Proportion of single-unit afferents responding to either DADLE (100nM) 
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Figure 5. The effects of chronic DSS supernatant on IBa. and neuronal excitability (A) Bars 
represent summary data for IBa in cultured DRG neurons incubated overnight with medium, 
control or chronic DSS supernatants. The amplitude of IBa inward currents in DRG neurons 
This article is protected by copyright. All rights reserved. 
incubated with medium was not significantly different from those incubated in control 
supernatant (open bar vs. grey bar). Chronic DSS supernatants produced a marked decrease in 
IBa (*p < 0.05) compared with medium and control supernatants. Number of cells appears in 
each bar. Bars represent mean ± SEM. *denote statistical significance by one-way ANOVA with 
Bonferroni’s post-test. The amplitude of inward currents was normalized to cell capacitance. 
(B) Dissociated DRG neurons were incubated overnight with chronic DSS supernatants plus
DAMGO (0.1 μM) or DADLE (0.1 μM). Neither DADLE nor DAMGO had not additional inhibitory 
effect on IBa. (C) Dissociated neurons were preincubated with MOR antagonist (CTOP 1 μM) or 
DOR antagonist (SDM25N 1 μM) 30 min before incubation with control (Ctl Sup) (left panel) or 
chronic DSS supernatants (cDSS Sup)(right panel). CTOP reversed the inhibitory effect of 
chronic DSS supernatants on IBa in cultured DRG neurons but SDM25N has no effect. (D) 
Rheobase recorded following incubation with cDSS supernatant is inhibited by both SDM25N 
and CTOP (left panel, * p < 0.05) and action potential discharge by CTOP (right panel, * p < 0.05). 
Bars represent mean ± SEM. Number of cells appears in each bar; * significant difference from 
control (P < 0.05, one-way ANOVA with Dunnett’s post-test). 
